Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies
January 19, 2021 08:30 ET | Source: Veru Inc. Veru Inc. Miami, Florida, UNITED STATES International Study Establishes the Role of Androgen Receptor as a Tumor Suppressor in ER+ Advanced Breast Cancer Preclinical Studies Support Enobosarm’s Novel Mechanism of Action as an AR Activating Agent as a Potential Therapy in Patients with ER+ Metastatic Breast Cancer that have Become Resistant to Current Standard of Care Treatments Veru Also Announces that the Enobosarm Phase 3 Registration ARTEST Study is on Track to Commence Next Quarter in Patients with Metastatic ER+ Breast Cancer that is Resistant to Estrogen Receptor Targeted Endocrine Therapy and CDK4/6 Inhibit
Study finds new evidence about the positive role of androgens in breast cancer treatment
Researchers at the University of Adelaide have found new evidence about the positive role of androgens in breast cancer treatment with immediate implications for women with estrogen receptor-driven metastatic disease.
Published today in
Nature Medicine, the international study conducted in collaboration with the Garvan Institute of Medical Research, looked at the role of androgens - commonly thought of as male sex hormones but also found at lower levels in women - as a potential treatment for estrogen receptor positive breast cancer.
Watch a video explainer about the new study at - https:/
New study finds androgens may be effective in treating breast cancer laprensalatina.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from laprensalatina.com Daily Mail and Mail on Sunday newspapers.
Adelaide [Australia], January 19 (ANI): Researchers at the University of Adelaide have found new evidence about the positive role of androgens in breast cancer treatment with immediate implications for women with estrogen receptor-driven metastatic disease.